Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows from Operating Activities:
Net loss from continuing operations	$ (9,736,181)	$ (16,196,312)
Loss from discontinued operations, net of tax	(1,252,276)	(2,406,124)
Gain on sale of discontinued operations	1,534,479	0
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of discontinued operations	(1,534,479)
Stock-based compensation	560,865	605,299
Depreciation and amortization of intangible assets	65,039	73,533
Amortization of right of use assets	93,682	(5,675)
Amortization of debt discount	19,549	22,479
Change in fair value of forward purchase agreement	5,700,451	10,592,442
Change in fair value of derivative liabilities		(826,980)
Shares issued for interest		250,000
Changes in operating assets and liabilities:
Prepaid expenses	331,235	(1,033,599)
Inventory	(97,890)
Accounts receivable and other current assets	(15,079)	28,175
Assets available for sale	4,662,980	4,748,384
Accounts payable	(202,940)	593,463
Accrued expenses and other liabilities	(1,260,865)	271,251
Lease liability	(96,112)	(75,219)
Accrued interest		577,007
Income taxes payable		187,126
Liabilities available for sale	(2,389,343)	(2,342,260)
Net cash used in operating activities	(3,616,885)	(4,937,010)
Cash flows from investing activities
Purchase of property and equipment		(30,470)
Cash paid in AxoBio Disposition	(748,796)
Net cash (used in) provided by investing activities	(748,796)	(30,470)
Cash Flows from Financing Activities:
Proceeds from issuance of Common Stock, net of costs	2,687,225
Proceeds from issuance of loans	495,692	1,859,980
Payment of loans	(592,372)	(106,631)
Gross proceeds from Business Combination		30,951,174
Transaction costs paid in connection with the Business Combination		(624,847)
Cash transferred in connection with Forward Purchase Agreement		(17,535,632)
Proceeds from common stock option exercises		41,064
Payment of convertible notes		(2,649,874)
Net cash provided by financing activities	2,590,545	11,935,234
Net (decrease) increase in cash	(1,775,136)	6,967,754
Cash - beginning of the period	2,912,461	128,149
Cash - end of the period	1,137,325	7,095,903
Supplemental cash flow information:
Interest paid	21,953	11,367
Income tax paid		423,754
Non-cash financing activity:
Fair value of shares received in AxoBio Disposition	23,456,179
Common Stock issued in connection with conversion of Promissory Notes	848,500
Decrease in right of use asset and lease liabilities related to termination of lease	$ 333,003
Net assets acquired in AxBio Acquisition		43,135,082
Earnout liability and deferred consideration payable in connection with AxBio Acquisition		21,482,292
Issuance of Series A preferred stock and common stock in connection with AxBio Acquisition		21,652,790
Accrued Legacy Series A preferred stock dividends		164,510
Accrued Legacy Series C-1 preferred stock dividends		40,551
Accrued Legacy Series C-2 preferred stock dividends		470,962
Debt discount recorded in connection with loans payable		55,062
Unpaid transaction costs incurred in connection with the business combination		1,186,219
Unpaid liabilities assumed in connection with the Business Combination		6,179,562
Conversion of common stock and preferred stock in connection with the Business Combination		$ 32,092,096